An­oth­er top Genen­tech ex­ec gets poached, this time tak­ing the helm at CAR-T play­er Bel­licum

One of the best com­pa­nies you can have on your re­sume in bio­phar­ma these days is Genen­tech. The com­pa­ny is cred­it­ed with 11 new drug ap­provals since Roche took over in 2009, in­clud­ing some block­buster ad­di­tions. And the re­sult­ing ex­o­dus of tal­ent now in­cludes Rick Fair, the head of on­col­o­gy glob­al prod­uct strat­e­gy, who is tak­ing over as CEO of the im­muno-on­col­o­gy play­er Bel­licum $BLCM.

Now ex-CEO Tom Far­rell is out, rel­e­gat­ed to a tem­po­rary role as com­pa­ny ad­vis­er dur­ing the tran­si­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER